Reweighed Charlson comorbidity index more accurate in men with prostate cancer

Article

A reweighed Charlson comorbidity index (CCI) based on prostate cancer-specific data and long-term follow-up predicts long-term, other-cause mortality in prostate cancer patients better than the original CCI.

Key Points

Washington-A reweighed Charlson comorbidity index (CCI) based on prostate cancer-specific data and long-term follow-up predicts long-term, other-cause mortality in prostate cancer patients better than the original CCI, according to UCLA researchers.

Based on its performance, the revised CCI may be useful for counseling men about management of early-stage prostate cancer, said first author Timothy Daskivich, MD, a urology resident at UCLA's David Geffen School of Medicine working with Mark S. Litwin, MD, MPH, and colleagues.

Related Videos
 Licensed   FILE #:  458906503  Preview Crop  Find Similar  Expand Image DIMENSIONS 8000 x 5333px FILE TYPE JPEG CATEGORY The Environment LICENSE TYPE Standard or Extended A lake in the shape of a recycling sign in the middle of untouched nature | Image Credit: © malp - stock.adobe.com
Dr. Mehmet Asim Bilen in an interview with Urology Times
Anne M. Suskind, MD, MS, FACS, FPMRS, answers a question during a Zoom video interview
blurred clinic hallway
Female doctor using laptop | Image Credit: © nenetus - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.